Phase 2 (NA-931, 13 weeks): Key characteristics: Lowest GI adverse event rates of any drug in this comparison by a wide margin 83% of all GI events classified as "insignificant" No clinically meaningful difference in GI events between NA-931 and placebo No muscle loss observed However, the study was only 13 weeks with 125 participants -- tolerability at higher doses and longer durations is unknown Side-by-Side Comparison# NR = not reported
The mechanisms through which CPT1A aids in cancer cell survival remain not fully clarified
The beyond-use date must be determined based on validated stability data for the specific preparation method and concentration used
The PIL highlighted their growing repurposing for aesthetic weight loss without India-specific clinical trials, safety evaluations, or regulatory safeguards, citing 82 deaths in the UK, pending lawsuits in the US, and serious health risks including pancreatitis, thyroid cancer, cardiovascular complications, and potential neurological damage
This risk is heightened when Zoloft is taken in conjunction with other medications that affect serotonin levels, underscoring the importance of a comprehensive medication review when Zoloft is prescribed
What purity are your research compounds